Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) EBITDA (2021 - 2025)

Historic EBITDA for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Q3 2025 value amounting to $7.4 million.

  • Arcutis Biotherapeutics' EBITDA rose 11813.56% to $7.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$44.9 million, marking a year-over-year increase of 7694.31%. This contributed to the annual value of -$140.0 million for FY2024, which is 4635.13% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported EBITDA of $7.4 million as of Q3 2025, which was up 11813.56% from -$15.8 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' EBITDA's 5-year high stood at $7.4 million during Q3 2025, with a 5-year trough of -$108.1 million in Q3 2022.
  • For the 5-year period, Arcutis Biotherapeutics' EBITDA averaged around -$50.2 million, with its median value being -$52.5 million (2024).
  • As far as peak fluctuations go, Arcutis Biotherapeutics' EBITDA crashed by 8969.31% in 2022, and later skyrocketed by 11813.56% in 2025.
  • Arcutis Biotherapeutics' EBITDA (Quarter) stood at -$71.6 million in 2021, then rose by 0.08% to -$71.5 million in 2022, then increased by 7.57% to -$66.1 million in 2023, then skyrocketed by 82.86% to -$11.3 million in 2024, then skyrocketed by 165.17% to $7.4 million in 2025.
  • Its EBITDA stands at $7.4 million for Q3 2025, versus -$15.8 million for Q2 2025 and -$25.2 million for Q1 2025.